Page 24 - ARNM-3-3
P. 24

Advances in Radiotherapy
            & Nuclear Medicine                                    Brachytherapy versus external beam in local dose escalation





                      Main results  No statistically   significant   differences for   LC, DMFS, OS, or   toxicity  The photon group  had more   recurrences of any   type compared to   the electron group   (p=0.02)  There was no   significant   difference in  5-year LC   according to the   boost technique  The DMFS rate   was significantly   higher in the EB   group and the IRT   group compared   to the PB group.   However, this   difference   disappeared after   adjustin






                      Median   FU  12 y (range:   10 – 16 y)  13.1 y   (range: 11.4   – 15.4 y)  5.3 y  8.8 y   (range: 0.5   – 12.0 y)



                      Late toxicity  IOERT:  Liponecrosis:   2 pts  -  EB:  Teleangectasia:   7.7%;  Fibrosis: 1.9%  MIRT-HDR:  Teleangectasia:   7.7%;  Fibrosis: 17.3%  -





                      Acute toxicity  IOERT:  Seromas: 7 pts;  Wound   healing: 3 pts  EBRT:  Seromas: 5 pts;  Wound   healing: 4 pts





                      OS   At 10 y,  IOERT:   91.6%;  EBRT:   94.3%;  p=0.377  -  -  -  -  -  At 10 y,  EB:   86.4%  PB:   80.2%  IRT:   89.2%


                      CSS                   At 10 y,  EB: 94.3%;  PB: 85.9%;  IRT: 92.7%

                           -                            -                -
                      DMFS7DFS  At 10 y,  IOERT: 84%;  EBRT: 80.9%;  p=0.529  At 10 y,  EB: 90.1%;  PB: 79.4%;  IRT: 87.8%  -  At 10 y,  EB: 90.6%;  PB: 81.6%;  IRT: 87.4% Abbreviations: CSS: Cancer-specific survival; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; EB: Electron boost; EBRT: External beam radiotherapy; fr: Fractions;   FU: Follow-up; Gy: Gray; HDR: High-dose rate; IOERT: Intraoperative radiotherapy with electrons; IRT: Interventional ra







                      LC     IOERT: 93.7%;  EBRT: 94.7%;    MIRT: 91.4%;                                interventional radiotherapy: n: Number; OS: Overall survival; PB: Photon boost; PDR: Pulsed-dose rate; pts: Patients; Rand: Randomized; Retr: Retrospective; y: Years.
                           At 10 y,  p=0.709  At 10 y,  EB: 97.9%;  PB: 97.9%;  IRT: 97.6%;  p=0.89  At 5 y,  EB: 94.2%;  p=0.74  At 10 y,  EB: 97.5%;  PB: 98.7;  IRT: 99.3%





                      Treatment  IOERT: 10 Gy/1 fr;  EBRT: 10 Gy/5 fr  EB: 16 – 20 Gy/8-10 fr;  PB: 16 – 20Gy/8 – 10 fr  IRT:  LDR – PDR: 15 – 20 Gy;  HDR: 8.5 Gy  EB: 16 Gy;  MIRT: 12 – 14.25 Gy  EB: 16 – 20 Gy/8 – 10 fr;  PB: 16 – 20Gy/8 – 10 fr;  IRT:  LDR–PDR: 15 – 20Gy



                   Table 1. Summary of breast cancer studies  n pts  Study  Period  IOERT: 113;  Rand  1999 –   EBRT: 112  2004  EB: 1448;  Retr  2000 –   PB: 97;  2007  MIRT: 334  EB: 52;  Retr  1995 –   MIRT-HDR:   1998  52  EB: 1052;  Retr  2000 –   PB: 76;  2005  IRT: 225














                           Ciabattoni
                      Authors




            Volume 3 Issue 3 (2025)  et al. 9  Kindts   et al. 10  Polgár   et al. 11  16  Verhoeven   et al. 12  doi: 10.36922/ARNM025160017
   19   20   21   22   23   24   25   26   27   28   29